Filtered By:
Therapy: Endocrine Therapy
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 2859 results found since Jan 2013.
How to Navigate the Treatment Spectrum from Multimodality Therapy to Observation Alone for ductal carcinoma in situ
Surg Oncol Clin N Am. 2023 Oct;32(4):663-673. doi: 10.1016/j.soc.2023.05.011. Epub 2023 Jun 15.ABSTRACTDCIS detection has increased dramatically since the introduction of screening mammography. Current guidance concordant care recommends surgical intervention for all patients with DCIS, followed by radiation and/or endocrine therapy for some. Adjuvant therapies after surgical excision have reduced recurrence rates but not breast cancer mortality. Given the lack of evidence of current treatment regimens and the morbidity associated with these treatments, there is concern that DCIS is over-treated. Active surveillance may be...
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Sydney M Record Eun-Sil Shelley Hwang Akiko Chiba Source Type: research
Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators
CONCLUSION: To generate nomograms that predicted DFS and OS, independent predictors of DFS in ER-positive/HER2-negative breast cancer patients were chosen. The nomograms successfully stratified patients into prognostic categories and worked well in both internal validation and external validation.PMID:37713046 | DOI:10.1007/s12094-023-03316-0
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Xinming Song Pintian Wang Ruiling Feng Mandika Chetry E Li Xiaohua Wu Zewa Liu Shasha Liao Jing Lin Source Type: research
Current treatment landscape of HR+/HER2- advanced breast cancer in the Nordics: a modified Delphi study
DISCUSSION: ET in combination with a CDK4/6 inhibitor is the preferred frontline treatment for HR+/HER2- aBC in the Nordics. The observed discrepancy between current guidelines and clinical practice could be due to differences in the reimbursement of novel treatments in the Nordics. Collaborative research efforts are warranted for topics that lack consensus.PMID:37713138 | DOI:10.1080/0284186X.2023.2254475
Source: Acta Oncologica - September 15, 2023 Category: Cancer & Oncology Authors: J ürgen Geisler Peeter Karihtala Malgorzata Tuxen Antonis Valachis Delphi Panellist Group Barbro Holm Source Type: research
Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators
CONCLUSION: To generate nomograms that predicted DFS and OS, independent predictors of DFS in ER-positive/HER2-negative breast cancer patients were chosen. The nomograms successfully stratified patients into prognostic categories and worked well in both internal validation and external validation.PMID:37713046 | DOI:10.1007/s12094-023-03316-0
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Xinming Song Pintian Wang Ruiling Feng Mandika Chetry E Li Xiaohua Wu Zewa Liu Shasha Liao Jing Lin Source Type: research
How to Navigate the Treatment Spectrum from Multimodality Therapy to Observation Alone for ductal carcinoma in situ
Surg Oncol Clin N Am. 2023 Oct;32(4):663-673. doi: 10.1016/j.soc.2023.05.011. Epub 2023 Jun 15.ABSTRACTDCIS detection has increased dramatically since the introduction of screening mammography. Current guidance concordant care recommends surgical intervention for all patients with DCIS, followed by radiation and/or endocrine therapy for some. Adjuvant therapies after surgical excision have reduced recurrence rates but not breast cancer mortality. Given the lack of evidence of current treatment regimens and the morbidity associated with these treatments, there is concern that DCIS is over-treated. Active surveillance may be...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Sydney M Record Eun-Sil Shelley Hwang Akiko Chiba Source Type: research
Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators
CONCLUSION: To generate nomograms that predicted DFS and OS, independent predictors of DFS in ER-positive/HER2-negative breast cancer patients were chosen. The nomograms successfully stratified patients into prognostic categories and worked well in both internal validation and external validation.PMID:37713046 | DOI:10.1007/s12094-023-03316-0
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Xinming Song Pintian Wang Ruiling Feng Mandika Chetry E Li Xiaohua Wu Zewa Liu Shasha Liao Jing Lin Source Type: research
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)
CONCLUSION: The results of the AMICA study show a promising efficacy and safety of maintenance treatment with ribociclib added to ET after at least stable disease following the first metastatic chemotherapy in patients with HR+/HER2-mBC.TRIAL REGISTRATION: Anti-hormonal Therapy With Ribociclib in HR-positive/HER2- Negative Metastatic Breast Cancer (AMICA), NCT03555877, https://clinicaltrials.gov/ct2/show/NCT03555877.PMID:37690320 | DOI:10.1016/j.breast.2023.08.007
Source: Breast - September 10, 2023 Category: Cancer & Oncology Authors: Thomas Decker Kerstin L üdtke-Heckenkamp Luidmila Melnichuk Nader Hirmas Kristina L übbe Mark-Oliver Zahn Marcus Schmidt Carsten Denkert Ralf Lorenz Volkmar M üller Dirk-Michael Zahm Christoph Mundhenke Stefan Bauer Marc Thill Peter Seropian Natalie Fi Source Type: research
< em > CYP2C19*17 < /em > association with higher plasma 4-hydroxy tamoxifen in Pakistani (estrogen-positive) breast cancer patients
This study was conducted to explore the influence of genetic polymorphisms in CYP2C19 gene on Tam's pharmacogenetics and pharmacokinetics in estrogen-positive BC patients. Data from healthy, unrelated individuals (n = 410; control group) and ER-positive BC patients (n = 430) receiving 20 mg of Tam per day were recruited. Steady-state plasma concentrations of Tam and its three metabolites were quantified using the high-performance liquid chromatography in the patients. The CYP2C19 polymorphisms were genotyped using an Amplification Refractory Mutation System-Polymerase Chain Reaction (ARMS-PCR) approach. More than 65% of he...
Source: Cancer Control - September 9, 2023 Category: Cancer & Oncology Authors: Muhammad Usman Tareen Sana Riaz Saima Shakil Malik Sana Zahid Anum Khursheed Fizza Tariq Faiza Abbas Muhammad Nouman Malik Riffat Aysha Anis Mariam Anees Iram Murtaza Aneesa Sultan Source Type: research
Oral Health Concerns of Female Breast Cancer Survivors on Adjuvant Endocrine Therapy
CONCLUSIONS: Data analysis showed that female breast cancer survivors taking adjuvant endocrine therapy appear more likely to have oral health issues than those not taking such therapy. Improved awareness of these issues is critical. Assessment and management guidelines to address these oral health issues are needed by health care providers.PMID:37678330 | DOI:10.1097/01.NAJ.0000978924.32557.53
Source: The American Journal of Nursing - September 7, 2023 Category: Nursing Authors: So-Hyun Park Shiela M Strauss Source Type: research
Treatment strategies for patients with resistant advanced breast cancer to CDK4/6 inhibitors
Zhonghua Yi Xue Za Zhi. 2023 Sep 12;103(34):2652-2656. doi: 10.3760/cma.j.cn112137-20230517-00815.ABSTRACTCDK4/6 inhibitors have become the standard of care for HR-positive, HER2-negative advanced breast cancer. However, there is still a lack of standard recommendations for the subsequent treatment of patients with CDK4/6 inhibitor resistance, especially those with primary resistance or rapid progression. Currently, appropriate treatment strategies included re-challenge of CDK4/6 inhibitors, combination with PI3K/AKT/mTOR inhibitors, new antibody drug conjugate (ADC), novel endocrine therapy drugs, and chemotherapy. In add...
Source: Cancer Control - September 7, 2023 Category: Cancer & Oncology Authors: Q F Zheng S S Wang Source Type: research
Oral Health Concerns of Female Breast Cancer Survivors on Adjuvant Endocrine Therapy
CONCLUSIONS: Data analysis showed that female breast cancer survivors taking adjuvant endocrine therapy appear more likely to have oral health issues than those not taking such therapy. Improved awareness of these issues is critical. Assessment and management guidelines to address these oral health issues are needed by health care providers.PMID:37678330 | DOI:10.1097/01.NAJ.0000978924.32557.53
Source: The American Journal of Nursing - September 7, 2023 Category: Nursing Authors: So-Hyun Park Shiela M Strauss Source Type: research
